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Abstract The burden of influenza is unevenly distributed,
with more severe outcomes in children aged <5 years than
older children and adults. In spite of this, immunisation
policies for young children are far from universal. This
article provides an overview of the published evidence on
the burden of influenza in children worldwide, with a par-
ticular interest in the impact of pandemic influenza in 2009–
2010 (caused by the H1N1pdm09 virus). In an average
season, up to 9.8 % of 0- to 14-year olds present with
influenza, but incidence rates can be markedly higher in
younger children. Children aged <5 years have greater rates
of hospitalisation and complications than their older coun-
terparts, particularly if the children have co-existing ill-
nesses; historically, this age group have had higher
mortality rates from the disease than other children, al-
though during the 2009–2010 pandemic the median age of
those who died of influenza was higher than in previous
seasons. Admissions to hospital and emergency departments
appear to have been more frequent in children with
H1N1pdm09 infections than during previous seasonal epi-
demics, with pneumonia continuing to be a common com-
plication in this setting. Outcomes in children hospitalised
with severe disease also seem to have been worse for those
infected with H1N1pdm09 viruses compared with seasonal
viruses. Studies in children confirm that vaccination reduces
the incidence of seasonal influenza and the associated
burden, underlining the importance of targeting this group
in national immunisation policies. Conclusions: Children
aged <5 years are especially vulnerable to influenza, partic-
ularly that caused by seasonal viruses, and vaccination in
this group can be an effective strategy for reducing disease
burden.
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Introduction
Influenza is disproportionate in its effect on different age
groups. For example, US children aged 0–19 years had a
higher risk of being infected with influenza A/H1N1 or
A/H3N2 than adults of any age during yearly epidemics
between 1977 and 1978 and 1980 and 1981, and in two
influenza B epidemics (1976–1977 and 1979–1980), the age
group at highest risk of infection was 5- to 14-year olds [77].
In a cohort of 209 US infants monitored weekly from birth
until the age of 1 year, 69 (33 %) developed influenza
infection [43]. More recent data tell a similar story: in the
first 10 months of the 2009–2010 influenza pandemic, the
hospitalisation rate in US children under the age of 5 years
with laboratory-confirmed influenza was more than double
that of any other age group [19], and among 722 patients
admitted to intensive care unit (ICU) with confirmed
H1N1pdm09 infection in Australia and New Zealand during
2009, the age-specific incidence of admission was higher in
infants <1 year old than in any other age group [6]. In
Germany, mortality rates in 2009–2010 were highest in
children in their first year of life and middle-aged adults
(aged 35–59 years) [102].
Since the 2008–2009 influenza season, influenza vacci-
nation has been recommended for children aged 6 months to
18 years in the USA [21]. In addition, the Influenza
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Working Group for the World Health Organisation Strategic
Advisory Group of Experts has recommended that children
aged 6 months to 5 years be considered as a target group for
annual influenza vaccination [100], and the UK Department
of Health recently announced a plan to vaccinate children
aged 2–17 years annually from 2014 [62]. However, in
many other European countries, routine immunisation of
children against influenza is not yet recommended. Cost-
effectiveness arguments certainly play a part in this, but it is
also possible that doubts remain about the burden that
influenza poses in children.
This article provides an overview (non-systematic review)
of published evidence on this topic. Most of the papers cited in
this article came from a search of the PubMed database on 27
April 2012 for articles published at any time in English or
Germanwith ‘influenza’ and any of the following words in the
title: child, children, schoolchildren, infant (and words with
‘infant’ as root), pediatric(s) or paediatric(s). The search field
was restricted to title only to produce a manageable number of
papers (1,686) for further searching. The results were searched
for publications relevant to our subject headings, with a focus
on recently published papers on the impact of the 2009–2010
influenza pandemic (infections with the H1N1pdm09 virus) in
children. No formal screening criteria were used, and addi-
tional publications not found by the search that contain data
pertinent to influenza burden in children are also cited.
Burden of influenza in children
Incidence and attack rate
The burden of influenza on communities worldwide is un-
even, because the annual disease epidemics vary consider-
ably in severity. Distinguishing the morbidity caused by
influenza from that due to influenza-like illness (ILI) caused
by other respiratory viruses, such as respiratory syncytial
virus (RSV) presents a challenge not only to epidemiolo-
gists but also to physicians in relation to diagnosis and
treatment. Nevertheless, a systematic review and meta-
analysis published in the Lancet in 2011 estimated that 90
million cases of influenza occur each year in children aged
<5 years around the world; of these, 20 million are associ-
ated with acute lower respiratory tract infections (LRTI),
one million of which are severe in nature [80]. By modelling
surveillance data on all ILI in four countries from 2002 to
2008, the European Paediatric Influenza Analysis project
calculated that between 0.3 and 9.8 % of children aged 0–
14 years present to a physician with influenza in the average
season [89]. These data are in line with the findings of an
earlier systematic review, by Bueving et al. [15], of 26
studies from a variety of countries and settings; although
the incidence of laboratory-confirmed influenza from
individual studies in that review ranged from 0 to 46 %,
two studies that measured incidence over a period at least of
5 years reported estimated incidences of 4.6 % for children
and adolescents aged ≤19 years [76] and 9.6 % for children
up to 5 years old [84]. Incidence rates could be even higher
in the youngest groups of children: during two seasons
considered to be milder influenza epidemics, namely
2000–2001 (primarily A/H1N1) and 2001–2002 (primarily
A/H3N2), the average annual rate of influenza in Finnish
children <3 years old seen as outpatients was 179/1,000
[51]. Surveillance in the USA over three seasons showed
that the cumulative rate of influenza-associated acute respi-
ratory illness was nearly twice as high in children aged 0–
18 years (median, 6 years) as in elderly adults (20 and 11 %,
respectively) [70].
The attack rate, i.e., the probability of people at risk of
becoming infected during an influenza outbreak, is often
reported as an outcome measure in vaccine efficacy trials.
For example, placebo group attack rates in a Japanese study
of 6- to 24-month-old children ranged from 7.2 to 12.5 %
over the three seasons 2000–2002 [73], and in German and
Finnish children aged <6 years, the placebo group attack
rates for seasons 2007–2008 and 2008–2009 were 2.4 and
5.2 % [125]. It is also of value for comparing the virulence
of infecting viruses from season to season, with clinical
attack rates (i.e. infected patients with symptoms) of 12–
24 % for seasonal influenza and 20 % for H1N1pdm09
influenza being reported in children up to 14 years old
[45, 50] and 3–16 % in infants aged 6–24 months [56].
The statistic should be interpreted with care, however, as
attack rates vary by season and geographic location
depending on the virulence of the infecting virus. For ex-
ample, clinical attack rates in a prospective cohort trial in
Finnish children were quite similar across the three age
groups studied (<3 years; 3–6 years, and 7–13 years) in
2000–2001, when A/H1N1 infections predominated, but in
2001–2002, when A/H3N2 predominated, the attack rate
was markedly higher in the youngest children (21.3 %) than
the oldest (3.0 %) [51]. In addition, infected individuals do
not always develop symptoms [133]; in recent German
surveillance, secondary H1N1pdm09 infections in adults
were significantly more likely to be asymptomatic than
those in children [104]. It is notable that during the 2009
pandemic, H1N1pdm09 seroprevalence rates in Germany
were nearly twice as high in 5- to 17-year olds (48 %) as
in 1- to 4-year olds (25 %) [127], in agreement with patterns
of mortality and hospitalisation rates described in later sec-
tions of this article.
Transmission and infectiousness
Children appear to be more vulnerable to developing infec-
tion when influenza is circulating. A study of household
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transmission from index cases with laboratory-confirmed
influenza found that children aged 0–5 years were signifi-
cantly more likely to develop clinical influenza than adults
(hazard ratio, 1.85; 95 % CI, 1.09–3.26) [126] and in a
prophylaxis study, the incidence of laboratory-confirmed
influenza in contacts aged 1–12 years receiving expectant
treatment was approximately three times as that in those
aged >13 years [48]. In 2008–2009, the risk of secondary
infections in German households with an influenza-infected
index case increased as the age of the household member
decreased, but in 2009–2010 (pandemic season), rates in
those aged 0–4 years were lower than any other age group,
with the highest risk in those aged 5–34 years [103].
Children with influenza contribute to the burden on all
age groups because of their high infectiousness [83]. In the
French transmission study mentioned above, the risk of
developing clinical influenza was significantly higher in
contacts exposed to infected children (aged 0–15 years) than
infected adults (aged >15 years) [126]. Prolonged viral
shedding may play a role in disease transmission. A long
duration of shedding was recently demonstrated in children
aged <15 years infected with H1N1pdm09 virus by Esposito
et al. [35]; at 9 days after influenza onset, 35/74 (47 %) were
still shedding virus and 14 (19 %) were still doing so at
day 13. Moreover, in households with children shedding
virus for at least 9 days, there was significantly more ILI
in the 2 weeks after the initial disease compared with chil-
dren shedding for <9 days [35].
From real-time surveillance of patient visits in a variety
of settings, children aged 3–4 years were consistently the
earliest age group to make healthcare visits during pneumo-
nia and influenza epidemics, so contributing to disease
spread beyond the household [14]. This idea is supported
by results of an influenza transmission model based on
children in Taipei, suggesting that children aged 4–6 years
have the highest transmission potential [24], although other
studies have found that older children are a more important
age group for transmission than younger children [42, 108,
127], probably because the opportunity for onward spread is
greater once children are attending school. As discussed in a
later section, vaccinating children can reduce the communi-
ty infection rate [8, 44, 94].
Influenza illness causes children to lose school time, and
their parents to lose work time, causing a socioeconomic as
well as a clinical burden. In Finland, influenza infections
were estimated to cause 216–274 days of absence from
school or day care and 54–195 parental work days lost for
every 100 children aged 0–13 years [51]. A US group
estimated that 247,000 work days/year were lost nationally
by caregivers of children who were taken to emergency
departments for influenza infections [13], and an Italian
study estimated that, including indirect costs of lost work
time, the mean cost of a childhood influenza infection was at
least €130 [34]. A study in Hong Kong found that school
absenteeism rates associated with influenza A epidemics
from 2003to 2004 to 2005to 2006 were much higher in
those aged ≤5 years (105–142 days/10,000 population) than
in those aged 6–17 years (15–20 days) [25].
Mortality rates
The 2011 meta-analysis by Nair and colleagues estimated
that between 28,000 and 111,500 children aged <5 years die
each year as a result of acute LRTI associated with influen-
za, and that 99 % of deaths happen in developing countries
[80]. Many other studies emphasise the relative vulnerabil-
ity of younger children with respect to the risk of dying from
influenza. In 2004–2007, the US Centres for Disease Con-
trol and Prevention (CDC) were notified of 166 influenza
deaths in children aged <18 years, with the median age of
these children being 5 years [37], and in the survey of
seasonal influenza deaths in US children published by Bhat
et al. [9], two thirds of deaths occurred in those aged
<5 years. In the latter study, the estimated mortality rate
associated with influenza was 0.21/100,000 children, but the
rates in age groups younger than 2 years old was 0.59 to
0.88/100,000 [9]. In an earlier study by CDC using data
from 1990 to 1999, estimated annual rates of underlying
respiratory and circulatory deaths associated with influenza
per 100,000 were 0.4 in children aged 1–4 years and 0.6 in
those aged <1 year [123]. Recent CDC estimates based on a
larger time span (1976–2007) suggest that average annual
rates for all ages could be 35 % lower than the 2003
estimates, although rates for young children were not calcu-
lated [18]. The mortality rate appears to be highest in those
aged <1 year for infections caused by either seasonal or
pandemic influenza viruses [38, 105]. As would be
expected, mortality risk is much higher when the infection
follows a more severe course. In H1N1pdm09-infected chil-
dren with severe illness admitted to ICUs, 81 % of whom
underwent mechanical ventilation, death rates were 47 %
[124]; many of these children had pre-existing illnesses such
as asthma and congenital heart disease, and co-infection
with RSV was found to be significantly associated with
mortality.
The influenza pandemic of 2009–2010 saw a spike in the
number of influenza-associated deaths in children compared
with previous seasons in the USA [29]. However, surveys in
the USA suggest a change in the age distribution of child
deaths during the pandemic. During the early part of the
pandemic (April to August 2009), 19 % of reported deaths
from H1N1pdm09 influenza in US children were in those
aged <5 years [17], yet more recent CDC data showed that
after the pandemic, nearly half (46 %) of all child influenza
deaths were in this age group [20], similar to the rate
calculated for under 5 years who died from seasonal
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influenza in 2007–2008 (Fig. 1) [92]. This is consistent with
a study showing the median age of US children who died
from H1N1pdm09 influenza being significantly higher than
in those who died in 2007–2009 from seasonal influenza
(9.4 and 6.2 years, respectively; p<0.01) (Fig. 2) [29].
However, some of the findings of a recent Dutch study
disagree with the US data described above. Using regression
modelling, this group estimated that influenza-related mor-
tality in Dutch children aged 0–4 years was much higher
during the 2009–2010 pandemic than the average of ten
previous seasons [131]; in the 5- to 24-year age group, the
estimated pandemic mortality was also higher than the sea-
sonal influenza average.
In more severely ill children, i.e. those requiring admis-
sion to an ICU, mortality rate was higher in those with
H1N1pdm09 infections than those with influenza A infec-
tions during previous seasons [55]. In the context of
H1N1pdm09 influenza, children with existing illness appear
to have had the highest mortality risk: roughly two thirds of
children who died after having H1N1pdm09 infections had
co-morbidities [17, 29, 105].
Clinical manifestations of disease
Influenza symptoms
The presenting symptoms of influenza in children do not
differ greatly between clinical settings. In children aged
<14 years who were treated as outpatients, fever was very
common (affecting 95 %), as were cough and rhinitis (77
and 78 % affected, respectively) but headache (39 %) and
myalgia (13 %) were less common [114]. An earlier
prospective study reported a high prevalence of fever, cough
and rhinorrhoea (95–96 %) in influenza-infected outpatients
<5 years old [96]. These three symptoms were almost as
common in hospital inpatients of the same age, with cough
slightly but significantly more common in those >6 months
old (94 %) than those up to 5 months old (80 %; p=0.01) [96].
Even in very young hospitalised infants (aged ≤2 months)
with confirmed influenza, fever was the main presenting
symptom [101]. Similarly, high rates of fever and cough were
reported from a more recent study of hospitalised children and
adolescents with H1N1pdm09 influenza [91]. Studies of
hospitalised influenza patients also report neurological symp-
toms, such as febrile convulsions [97, 115, 119], although
these are often reported as complications of the disease rather
than symptoms (see next section). As well as the neurological
system, other non-respiratory systems can be commonly af-
fected in influenza: in some epidemics, up to 50 % of children
have presented with gastrointestinal symptoms such as
vomiting and diarrhoea, particularly those who are admitted
to hospital, and affecting children of all age groups [1, 11, 67,
69, 90, 134]. In a study of children and adolescents
hospitalised with laboratory-confirmed influenza, sepsis-like
illness was the admission diagnosis for 52 % of those aged
<6 months and for up to 16 % of older children [115].
Differentiating influenza from other respiratory infec-
tions on the basis of symptoms alone is challenging, and
virological testing is necessary to confirm the diagnosis. A
Finnish group who used a matched case-control study in
children aged ≤13 years to compare confirmed influenza
patients with those who had respiratory symptoms but were
influenza-negative found fever to be the only reliable pre-
dictor of influenza [54].
Fig. 1 Deaths from influenza in US children <5 years old as a
proportion of all child deaths, comparing H1N1pdm09 influenza in
summer 2009 with seasonal influenza in 2007–2008 and 2010–2011
[17, 20, 92]
Fig. 2 Distribution of influenza-related deaths in children by age
group, comparing H1N1pdm09 influenza in April 2009–January
2010 with seasonal influenza in October 2007–April 2009. The differ-
ence in median ages was statistically significant (p<0.01) [29]
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Complications of influenza
Influenza-associated complications contribute significantly to
the disease burden in children. Complications are more likely
to develop in recognised high-risk groups, including those
with co-morbidities [26, 71] and younger children [71].
One of the most common complications of seasonal influ-
enza in children is otitis media, which is associated with excess
healthcare visits, antibiotic use and surgical procedures, and
can lead to hearing loss. Otitis media affected 28 % of under
5 years presenting as outpatients in the US population-based
study by Poehling et al. [96] and occurred in 24 % of young
hospitalised children in both a Finnish and a US study [90, 93].
Infants and young children aged under 2 years old, however,
appear to be at higher risk of acute otitis media than older
children [84], which is consistent with the results of the
Finnish prospective cohort study that reported a rate of 40 %
in children <3 years old in an outpatient setting [51].
Respiratory tract infections (RTIs) are also frequently
encountered as influenza complications. The most important
RTI with respect to healthcare burden is pneumonia which is
associated with hospitalisation and poorer outcomes. The
incidence of pneumonia is high in children admitted to
hospital with more severe influenza; in 2,992 hospitalised
children and adolescents with seasonal influenza, radio-
graphic evidence of pneumonia was found in 1,072 (36 %)
[30], and recently published studies in European and Asian
children suggest a similar rate in hospitalised children with
H1N1pdm09 influenza, with estimates ranging from 22 to
43 % [11, 69, 91, 111], although two groups found the rate
to be higher for H1N1pdm09 infections during 2009 than
for influenza A infections in previous seasons [5, 78]. Pneu-
monia is less common outside the hospital setting: in the
Finnish prospective cohort study in outpatients mentioned
above, pneumonia was diagnosed in 9 of 370 (2.4 %) chil-
dren with confirmed influenza, 8 of whom were aged
≤6 years [51]. In a retrospective study of 936 children aged
0–15 years with confirmed influenza seen as hospital out-
patients or inpatients, pneumonia was present in 134 (14 %)
children, 66 % of whomwere <3 years old [65]. As with otitis
media, infants aged under 2 years appeared to have a higher
risk of LRTI than those aged 2–4 years in a 25-year cohort
study, although absolute rates were quite low (annual rates per
1,000 children of 11 and 10 in the first and second years of
life, respectively, and 4 for those aged 2–4 years) [84].
Neurological events or disorders are frequently reported
as complications of influenza, ranging from febrile convul-
sions, which typically have a good prognosis, to encephalitis
and encephalopathy, which may be fatal.
Japanese and Taiwanese children appear to have a higher
vulnerability to CNS complications, although these findings
may be the result of more intense surveillance. In 1,000
Japanese patients aged 0–20 years with H1N1pdm09,
neurological complications resulted in hospital admission in
255 (25.5 %) patients; the most common events were febrile
convulsions (135 children) whereas encephalopathy, mostly
mild, was only seen in 12 [121]. CNS dysfunction occurred in
26 of 84 (31 %) Taiwanese children with seasonal influenza,
60 of whomwere aged <5 years; one of the patients had febrile
convulsions, but 21 had encephalitis or encephalopathy [128].
In a recent Israeli study, 14 of 74 (19 %) children aged 0–
16 years hospitalised with H1N1pdm09 had CNS complica-
tions, but these were mainly mild seizures [66].
CNS complications were less common in US studies of
seasonal and pandemic influenza. In the earlier survey, 72/842
children hospitalisedwith seasonal influenza (8.6%) had CNS
complications; 56 had seizures (median age, 1.4 years) and 10
(median age, 3.5 years) had mild encephalopathy [85]. In 307
children aged 1–19 yrs who were hospitalised with
H1N1pdm09 infection, 23 (7.5 %) had CNS complications
(17 with seizures and 7 with encephalopathy), but 15 patients
required monitoring in ICU and three died [64].
Neurological complications appear to be more common in
severely ill children. In a French study of 181 children admit-
ted to hospital with H1N1pdm09, 14 (7.7 %) had CNS dys-
function; of the 14 children (median age, 5.1 years), eight had
febrile seizures and three had encephalitis or encephalopathy
[39]. Twenty-four of the 181 children needed admission to
ICU, however, including nine of those with CNS complica-
tions (38 % of the ICU cohort). In a study of 20 German
children aged 0–15 years (median 7.5 years) who were admit-
ted to ICU with severe seasonal influenza infections, enceph-
alitis or encephalopathy occurred in five cases [120].
Less common complications of influenza include myosi-
tis [16, 57, 66, 90] and myocarditis [98, 112].
Hospitalisation rates in influenza patients
Several studies demonstrate that the burden of hospital
admission and emergency department visits in younger
children who are infected with influenza is considerable
[12, 13, 81, 84, 86]. Younger children are much more
likely to be hospitalised as a result of influenza and its com-
plications than their older counterparts. As shown in Table 1, a
number of surveys have reported that influenza-associated
hospitalisation rates were higher in those aged <5 years than
aged ≥5 years. Furthermore, studies consistently report that
the highest rates of all are in infants in their first year of life [4,
59, 81, 96, 107, 109, 116].
A 5-year survey of admissions to two children’s hospitals
in Kiel, Germany, compared incidence rates for types A and
B influenza; the cumulative population-based rates per
100,000 children aged 0–5 years were 123 and 30 for influ-
enza A and B, respectively, whereas rates in those aged 6–
16 years were 22 and 9, respectively [130]. The authors also
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noted that co-existing cardiac disorders and asthma increased
the risk of hospital admission in influenza A patients, in
agreement with earlier data from US studies showing that
high-risk children, e.g., those with asthma, are more likely to
be hospitalised or to have prolonged hospital stays compared
with otherwise healthy children [26, 82]. The higher-risk
group also have poorer outcomes than low-risk patients after
hospitalisation [110], and more than 50% of the hospital costs
of US children aged ≤18 years with an influenza diagnosis
was in higher-risk children alone [47].
Recent papers on epidemiology and outcomes in
hospitalised children have compared H1N1pdm09 influenza
with historical data on seasonal influenza. Some of these stud-
ies report a worsening of the disease burden with H1N1pdm09
influenza, either as higher hospitalisation or mortality rates or
more severe disease [31, 55, 68, 135] and others report large
increases in the hospitalisation rate for ILI during the first
months of the pandemic compared with previous seasons [75,
118]. Consistent with the experience from previous pandemics,
hospitalised children with H1N1pdm09 infections were signif-
icantly older than those hospitalised with seasonal influenza
(range ofmedian ages, 2–5 and 0–2 years, respectively) [31, 55,
118, 135]. A study on the impact of H1N1pdm09 influenza in
Japan suggested that although infants <1 year old were
hospitalised at a higher rate than those aged 12–23 months,
agreeing with the historical data for seasonal influenza de-
scribed above, those in their second year of life had three times
the rate of influenza-related complications [122].
Managing the influenza burden
Vaccination
A large systematic review of vaccine studies, published in
2012, concluded that live attenuated influenza vaccines
(LAIVs) and inactivated vaccines have similar effectiveness
in preventing influenza in children >2 years old (33 and
36 % respectively), but that in children aged ≤2 years,
inactivated vaccines (the only type licensed for use in this
age group) were no more effective than placebo [61]. Au-
thors of another systematic review and meta-analysis found
that vaccine effectiveness in children aged 6–59 months was
only significant in three of eight seasons, and concluded that
there is a need to improve the effectiveness of current
influenza vaccines [87]. A prospective, non-randomised
cohort study on trivalent inactivated influenza vaccine
(TIV) not included in the Cochrane review showed 66 %
effectiveness in preventing infection both in children aged
9 months to 3 years and, notably, in the subgroup of infants
aged under 2 years [53]. Adding the oil-in-water adjuvant
MF59 to TIV appears to boost vaccine efficacy further, as
shown in children aged 6 months to 6 years in a randomised
study [125]. Most recently of all, a meta-analysis of eight
trials (two-season and single-season) in children 2–17 years
old found that intranasal LAIV reduced influenza illness
caused by all strains by 79 % compared with placebo and
by 48 % compared with TIV [3].
Evidence from several countries suggests that vaccination
against seasonal influenza can reduce disease burden. In a
randomised placebo-controlled study in Italian children aged
6 months to 14 years, intranasal TIV reduced the mean num-
ber of missed school days (5.4 and 13.8 days, respectively)
and the mean number of lost work days in household contacts
(0.42 and 2.50), although no 95 % CI were reported [32]. A
similar single-season study in Sardinia, in younger children
(1–6 years old) showed that TIV significantly reduced the rate
of ILI compared with no treatment (12.4 and 37.7 %, respec-
tively (risk reduction of 67 %; 95 % CI, 59–74 %)) and the
mean duration of absenteeism from day care centres (0.5 and
2.3 days; no 95 % CI given) [28]. Over six consecutive
seasons in Japan, a non-randomised community-based study
Table 1 Seasonal influenza-associated hospitalisation rates in children
Location Period Hospitalisation rate per 100,000 Reference





(infants to older children)
Oregon, USA;
high-risk children
1967–1973 470 210 2.2 Mullooly and Barker [79]
Oregon, USA;
all children
1967–1973 120 40 3 Mullooly and Barker [79]
Tennessee, USA 1973–1993 86–1,038a 41 2.1–25.3 Neuzil et al. [81]
Seattle, USA 1992–1997 100 16 5.6 Izurieta et al. [59]
California, USA 1993–1997 135 19 7.2 Izurieta et al. 59]
Kiel, Germany;
influenza A only
1996–2001 123 22 5.6 Weigl et al. [130]
3 US counties 2000–2004 90 – – Poehling et al. [96]
a Range of rates reported; lowest value is for those aged 36–59 months and highest for those aged <6 months
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showed a small but significant difference in the aggregate rate
of hospitalisation associated with influenza A infections in
children aged 6–59months who were given two doses of TIV;
rates were 0.6% and 2.0% in the vaccinated and unvaccinated
groups, respectively (71% risk reduction [95%CI, 59–80%])
[63]. In a US study of the 2003–2004 season, two doses of
inactivated vaccine reduced the risk of an ILI office visit in
infants aged 6–21 months by 69 % (hazard ratio 0.31; 95 %
CI, 0.26–0.36%), although one dose was not effective [2]. In a
cost-effectiveness analysis of a 2-year randomised placebo-
controlled trial, intranasal LAIV reduced the mean number of
ILI fever days per child by 1.2 days in US children aged 15–
71 months, although the statistical significance was not
reported [72].
As reducing the number of cases in children makes
onward transmission in households less likely [58], societal
benefits of childhood vaccination are not only predicted by
modelling studies [8, 41, 95] but also borne out in practice.
Analysis of deaths attributable to pneumonia and influenza
in Japan from 1950 to 2000 suggested that the lower rate of
excess deaths during the middle three decades was probably
due to vaccine-induced herd immunity resulting from the
child immunisation programmes that operated from 1962 to
1994 [99], and later statistical analysis of these data, com-
paring the 1978–1994 and 1995–2006 periods, estimated
that the programmes had reduced mortality risk in adults
≥65 years by 36 % (95 % CI, 17–51 %) after adjusting for
virus subtype, population demographics and baseline mor-
tality risk [23]. Lower rates of ILI in other age groups
followed vaccination of children in Russia and the USA
[40, 94]. Complication rates are also lower in vaccinated
children, notably the incidence of otitis media [10, 32, 49,
74, 88] and the rate of respiratory illness in children with
asthma [117].
Influenza vaccines cause fever and myalgia, and
administration-site-related reactions such as pain and swell-
ing (and nasal congestion for the intranasal vaccine), which
are usually mild and temporary. A more serious but rare
side-effect is allergic reactions, and adverse reactions such
as febrile convulsions [7, 22] and narcolepsy [61] have been
reported to be associated with specific vaccine brands.
Antiviral agents
The neuraminidase inhibitors oseltamivir and zanamivir are
preferred to amantadine and rimantadine as influenza
antiviral therapy because of lower rates of drug resistance.
Systematic reviews of studies in children showed evidence
of their usefulness in shortening influenza duration and
reducing the incidence of acute otitis media in paediatric
seasonal influenza, although reduction in the incidence of
symptomatic influenza after prophylactic use was only mod-
est, and their ability to reduce the incidence of serious
influenza complications has yet to be proved in large trials
[113, 129]. A recent Cochrane review that examined regu-
latory information on neuraminidase inhibitors, principally
from trials in adults but including some in children, was
unable to reach conclusions about the effect of oseltamivir
on complications and transmission [60]. Recent studies re-
port that prompt initiation of oseltamivir treatment can
shorten hospital stay in children with severe influenza,
whether caused by seasonal virus strains or H1N1pdm09
virus [27, 36]. Seasonal H1N1 viruses developed naturally
occurring resistance to oseltamivir, particularly in the 2007–
2009 period [33, 106], but H1N1pdm09 viruses that
emerged during the 2009 pandemic appear to be mostly
sensitive to inhibition [46]. Oseltamivir appears to be very
effective for reducing otitis media incidence in children
aged 1–3 years, if treatment is started quickly (within 12 h
of symptom onset) [52]. WHO guidelines recommend the
use of neuraminidase inhibitors in children in high-risk
groups and in all children with severe influenza [132],
although there are still challenges, e.g. timely diagnosis,
when selecting patients who could benefit from therapy.
Children treated with oseltamivir have a significantly
higher rate of vomiting compared with placebo, but the
adverse event profile of neuraminidase inhibitors is other-
wise similar to that of placebo [129]. Neuropsychiatric side-
effects have been reported in association with oseltamivir
administration, although the significance of this is uncertain
given that CNS complications are often reported in
untreated influenza patients, as already described.
Conclusions
Many of the additional data on influenza in children that
have been published in 2009–2012 relate to infections
caused by the H1N1pdm09 virus. Some studies report that
hospitalisation rates for H1N1pdm09 infections were higher
than for seasonal influenza infections, and pneumonia con-
tinues to be at least as significant a complication as it was
before the arrival of the 2009–2010 pandemic. In contrast,
death rates in children under 5 years of age seem to have
been lower during the pandemic than they were before and
after it and in line with this, there was a difference in the
median age of those hospitalised, with pandemic influenza
typically affecting children 2–3 years older than those
with seasonal influenza. A common theme that does
emerge, however, is that young children remain particu-
larly vulnerable to influenza, with greater rates of
hospitalisation and complications than their older coun-
terparts, and the burden is worse still in children with co-
existing illnesses. The recent data on the effectiveness of
vaccines against seasonal influenza supports previous ex-
perience, showing that this is a productive strategy for
Eur J Pediatr (2014) 173:265–276 271
reducing disease burden in children, although more effec-
tive vaccines need to be developed.
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